TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
AXSM

Axsome Therapeutics Inc

Healthcare · Biotechnology

196.00$ +1.3% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Income Statement AXSM
Line item 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
– – – – – – – – – +467.3% +440.8% +42.5% +65.5%
– – – +478.3% +107.8% +15.0% -23.7% +108.2% +1,387.0% +349.8% +401.4% +27.8% +42.6%
– – – – – – – – – – +445.4% +44.1% +67.7%
– +178.7% +58.4% +212.8% -5.9% +17.7% +128.3% +30.9% -17.3% -0.2% +69.0% +91.0% -2.0%
– +357.9% +73.7% +162.2% +13.6% +29.8% +45.4% +112.5% +130.6% +86.0% +79.8% +39.2% +84.0%
– +208.4% +62.1% +199.5% -1.4% +20.9% +104.3% +47.7% +25.8% +80.1% +112.1% +32.9% +20.1%
– – – – – – – – – – – – –
– +582.6% -59.0% -85.5% +912.1% -15.9% +10.0% +107.0% +122.0% +28.8% -12.0% +1.8% -0.2%
– – – – – – – – – – – – –
– – – -56.9% +121.4% +131.8% -55.4% +85.5% +82.5% +134.2% -91.0% -91.1% -723.5%
– – – – – – – – – – – – –
– – – – – – – – – – – – –

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?